| Literature DB >> 31726045 |
Aixiao Xu1, Ning Zhang2, Ji Cao1, Hong Zhu1, Bo Yang1, Qiaojun He1, Xuejing Shao3, Meidan Ying4.
Abstract
Retinoic acid (RA) is a well-known differentiation inducer that exerts its effects by binding to nuclear RA receptors. Retinoic acid receptor α (RARα), as an important nuclear RA receptor, is activated upon RA binding and facilitates the transcription of target genes related to differentiation, which ultimately initiates cell differentiation. Previous studies have found that the transcriptional activity of RARα is regulated by various post-translational modifications, which influence its DNA binding efficiency, transactivation ability and even lead to degradation. Post-translational modifications of RARα, as a consequence, play an important role in the RA-induced differentiation process. Therefore, in this review, we focus on recent advances in the understanding of how these modifications affect the activity of RARα as well as strategies to increase the differentiation effect of RA treatment in cancer cells based on RARα modifications, which may promote the development of novel effective differentiation therapies for cancer treatment.Entities:
Keywords: Differentiation therapy; PTMs; RARα; Retinoic acid
Year: 2019 PMID: 31726045 DOI: 10.1016/j.bcp.2019.113696
Source DB: PubMed Journal: Biochem Pharmacol ISSN: 0006-2952 Impact factor: 5.858